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EndocytosisRecently, we showed that tetrasaccharide selectin ligand SiaLeX provided targeted delivery of liposomes loaded
in the bilayer with melphalan lipophilic prodrug to tumour endothelium followed by severe injury of tumour
vessels in a Lewis lung carcinoma model. Here, we study the impact of SiaLeX ligand on the interactions of lipo-
somes with human umbilical vein endothelial cells (HUVEC) using ﬂow cytometry, spectroﬂuorimetry and con-
focal microscopy. Liposomes composed of egg phosphatidylcholine/yeast phosphatidylinositol/1,2-dioleoyl
glycerol ester of melphalan, 8:1:1, by mol, and varying percentages of lipophilic SiaLeX conjugate were labelled
with BODIPY-phosphatidylcholine. The increase in SiaLeX content in liposomes led to a proportional increase
in their uptake by cytokine-activated cells as opposed to non-activatedHUVEC: for 10% SiaLeX liposomes, binding
avidity and overall accumulation increased 14- and 6-fold, respectively. The early stages of intracellular trafﬁc of
targeted liposomes in the activated cellsweremonitored by co-localisationwith the trackers of organelles. Endo-
cytosis of SiaLeX liposomes occurred mostly via clathrin-independent pathways, which does not contradict the
available literature data on E-selectin localisation in the plasma membrane. Using dual ﬂuorescence labelling,
with rhodamine-labelled phospholipid and calcein encapsulated at self-quenching concentrations, we found
that SiaLeX liposomes undergo rapid (within minutes) internalisation by activated HUVEC accompanied by the
disruption of liposomes; non-activated cells consumed a negligible dose of liposomes during at least 1.5 h. Our
data evidence the selective effect of SiaLeX formulations on activated endothelial cells and indicate their potential
for intracellular delivery of melphalan lipophilic prodrug.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Clinically useful antitumour effect produced by systemic administra-
tion of approved liposomal formulations of a speciﬁc size range
(100–200 nm) generally relates to liposome accumulation in tumours
owing to the leaky vasculature and impaired lymphatic drainage char-
acteristic of most pathological tissues (enhanced permeability and re-
tention effect, EPR) [1]. Further gain in selective delivery of cargo to
tumour cells and expectable rise of therapeutic efﬁcacy of a liposomal
drug could be achieved through ligand-mediated targeting. A wideIPY-8)heptanoyl]-sn-glycero-3-
salts; EDTA, ethylenediamine
ial cells; Mlph-DOG, rac-1,2-
te-buffered saline; PC, phospha-
hyde; PI, phosphatidylinositol;
amine B sulfonyl); SiaLeX, Sialyl
oxymethylene[poly(8–15)oxy-
necrosis factor alpharange of ligands were proposed for targeting of liposomes to tumour
cell–speciﬁc receptors, primarilymonoclonal antibodies to tumour anti-
gens (immunoliposomes) [2]. However, only a few examples of thera-
peutic advance of targeted over non-targeted liposomes have been
reported, all being related to the treatment of haematological malig-
nancies, micrometastases and tumour vasculature, where vascular and
interstitial barriers do not impede the delivery of nanosized vehicles
(reviewed in [1]). Moreover, differentiation of tumour cells into various
clones ofmalignant cells, including those resistant to the drug, results in
temporal and spatial heterogeneity of tumour and thus failure of
therapy speciﬁcally targeted to primary tumour cells. Targeting the
angiogenic vasculature, which ensures the survival and growth of
tumour tissue, is assumed a promising approach to overcome these
shortcomings ([3] and references therein). For targeting vascular endo-
thelial cells, sterically stabilized liposomes bearing RGD peptide
covalently linked to the polyethylene glycol (PEG) termini (to target
αν-integrins [4,5]) or VEGFR2 antibody (to target VEGF receptor [6])
were proposed.
E-selectin is recognized as another challenging target for delivery to
tumour endothelium [7,8]. Selectins\carbohydrate-binding cell
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endothelial cells (E- and P-selectins), circulating leukocytes (L-selectin)
and activated platelets (P-selectin). Selectin ligands comprise a variety
of sialylated and fucosylated carbohydrates containing tetrasaccharide
Sialyl Lewis X (SiaLeX, Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ) as a
common epitope [9]. Selectins play key roles in a wide variety of phys-
iologically important processes, including themigration of leukocytes to
areas of inﬂammation andmetastasis of cancer cells, throughmediation
of leukocyte tethering and rolling on activated endothelium [10,11]. The
dominant role of selectins in cancer progression has recently been con-
ﬁrmed in several preclinical knock-down experiments in SCID mouse
models. The crucial contribution of E- and P-selectins to spontaneous
metastasis formation was demonstrated in a clinically relevant model
of colon cancer [12], and E-selectin has been proven a potent target
for inhibition of melanoma angiogenesis and growth [13].
Not so many studies have been reported on drug-loaded liposomes
targeted to tumours and inﬂammation foci by the engrafted ligands of
E-selectin\monoclonal antibodies (immunoliposomes) or SiaLeX
(glycoliposomes) (reviewed in [7]). For example, anti-E-selectin PEG-
immunoliposomes encapsulating dexamethasone were shown to be a
powerful strategy for the treatment of glomerulonephritis in a murine
model [14]. The ﬁrst SiaLeX-conjugated liposomes, stabilised by PEG
coating, were proposed in [15]; this study in a felinemodel demonstrat-
ed the anti-inﬂammatory cardioprotective effect of the drug-free for-
mulation. Further studies demonstrated the inhibition of both cell
adhesion to immobilised E-selectin in a concentration-dependent man-
ner [16] and tumour cell adhesion to vascular endothelium in vitro [17]
by the SiaLeX liposomes. The feasibility of similar SiaLeX-bearing formu-
lations for the delivery of drugs to activated endothelial cells was dem-
onstrated in vitro [18]. Another type of glycoliposome was equipped
with a large portion of ganglioside GM1 linked to SiaLeX ligand through
human serum albumin and also bore hydrophilic coatingwith Tris mol-
ecules to prevent opsonisation [19–21]. These ﬂuorescently labelled li-
posomes were shown to target inﬂammatory and tumour sites in vivo
[19] and, after encapsulation of cisplatin, exhibited moderate yet reli-
able gain in tumour growth inhibition over SiaLeX-free counterparts in
a mouse xenograft model of lung carcinoma [20]. Recently, a study
employing SiaLeX-bearing formulations loaded with colloidal gold [21]
evidenced their potential to deliver encapsulated contents into inﬂam-
matory cells around synovial blood vessels in arthritic joints.
Earlier, we showed the signiﬁcant therapeutic advantage of lipo-
somes loaded with a lipophilic prodrug of sarcolysin (D,L-melphalan)
in the bilayer and supplemented with a mono-alkyl conjugate of SiaLeX
over SiaLeX-free formulations in a mouse breast cancer model [22]. The
pronounced superiority of cytotoxic SiaLeX-modiﬁed liposomes might
be ascribed not only to killing malignant cells but also to the blockageFig. 1. Schematic representation of a liposome loaded with a lipophilic prodrug and a targeting
(Mlph-DOG) and Sialyl Lewis X (SiaLeX-PEG8–15-DOG) used in this work are shown as well.of tumour vascularisation. Recently, we demonstrated that liposomes
loaded with melphalan diglyceride ester (Mlph-DOG; Fig. 1) and
equipped with the diglyceride conjugate of SiaLeX caused rigorous inju-
ries of tumour vessels in a Lewis lung carcinoma model [23]. Non-
targeted liposomes were shown to extravasate in tumour tissue, while
liposomes equippedwith SiaLeX adhered to the endothelium of tumour
vessels and produced antivascular effect through apoptotic cell death
[23]. We assume that the effect is realised through internalisation of
SiaLeX liposomes by endothelial cells leading to cell disruption due to
the cytotoxic action of melphalan generated from the prodrug intracel-
lularly. The goal of this work was to study the details of the interactions
between endothelial cells and liposomes loaded with Mlph-DOG.
The cell cycle non-speciﬁc alkylating agent melphalan is still indis-
pensable in the treatment of multiple myeloma and metastasizing
tumours and continues to be the core ofmany combination therapy reg-
imens (e.g. [24]). However, attempts to efﬁciently encapsulate melpha-
lan per se in a nanoparticulate carrier, which would reduce its severe
side effects, have failed. We produced stable 100-nm liposomes with
satisfactory loading capacity (cargo-to-lipidmolar ratio of 1:9) by incor-
poration of the drug in the lipid bilayer in the form of an appropriately
designed lipophilic prodrugMlph-DOG [25,26]. The bilayer is composed
of natural ﬂuid-phase phospholipids and contains phosphatidylinositol
as a stabilizing component to reduce premature withdrawal of lipo-
somes from the circulation by the cells of the reticuloendothelial system
[27]. Phosphatidylinositol presumably decreases opsonisation of lipo-
somes, since inositol moieties generate highly hydrated coating on the
surface of the bilayer, which shields the lipid membrane [28] similarly
to PEG chains. In this study, to compare the inﬂuence of SiaLeX targeting
ligand on the interactions of our formulation with activated and non-
activated endothelium, we used primary cultures of human umbilical
vein endothelial cells (HUVEC). Keeping in mind that Mlph-DOG is a
component of the lipid bilayer, we examined binding and
internalisation of liposomes by HUVEC using several ﬂuorescence tech-
niques and revealed some details of the endocytosis process.2. Materials and methods
2.1. Materials
Phosphatidylcholine (PC) from egg yolk and phosphatidylinositol
(PI) from S. cerevisiae were obtained from Reakhim (Russia). A con-
jugate of a tetrasaccharide Sialyl Lewis X 3-aminopropyl glycoside
and rac-1,2-dioleoyl-3-carboxymethylene[poly(8-15)oxyethylene]
oxyacetylamidopropionylglycerol (SiaLeX-PEG8–15-DOG) [29], rac-1,2-
dioleoylglycerol ester conjugate of melphalan (Mlph-DOG) [30] and 1-tetrasaccharide conjugate. Chemical structures of the lipophilic conjugates of melphalan
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(BODIPY-PC) [31] were synthesized as previously reported.
Fluorescent probes and trackers used in the study were the
following: BODIPY-PC; Rhod-PE (L-α-phosphatidylethanolamine-N-
(lissamine rhodamine B sulfonyl) obtained from Avanti Polar Lipids,
#810146); ER-Tracker™ Red (Molecular Probes, #E34250, ~1 μM
working solution); Transferrin Alexa Fluor® 555 conjugate (Molecular
Probes, #T35352, 20 μg/mL working solution); wheat germ agglutinin
(WGA) Alexa Fluor® 555 conjugate (Molecular Probes, #W32464,
10 μg/mL working solution); and Alexa Fluor® 555 F(ab′)2 fragment
of goat anti-mouse IgG (H+ L) secondary antibody (Molecular Probes,
#A21425, 1:2000 dilution). Mouse monoclonal anti-human E-selectin
antibody was purchased from Santa Cruz Biotechnology (#2Q780,
1:100 dilution). Human recombinant tumour necrosis factor alpha
(TNF-α) was a kind gift from Dr. L.N. Shingarova (IBCh RAS).2.2. Liposome preparation
Liposomes composed of PC–PI–Mlph-DOG, 8:1:1(by mol), either
equipped with 2–10 mol.% glycoconjugate SiaLeX-PEG8–15-DOG or not
(control), were prepared as described earlier [23]. Brieﬂy, dry lipid
ﬁlms were hydrated in PBS (1.5 mM KH2PO4, 1.1 mM NaH2PO4°2H2O,
6.3 mM Na2HPO4, 2.7 mM KCl and 136.8 mM NaCl; pH 7.2) and sub-
jected to 6–10 cycles of freezing/thawing (liquid nitrogen/+40 °C).
The suspension was then extruded at ambient temperature through
two stacked polycarbonate membrane ﬁlters with pore sizes of
100 nm (Nucleopore), 10 times, on a Mini-extruder (Avanti Polar
Lipids). The size of the liposomes was controlled by dynamic light
scattering using a 90Plus (Brookhaven Instruments Corp.) equipment
in at least three runs per sample. Mean liposome diameter was in the
range of 90–100 nm. To visualize liposomes, 0.5 mol.% of BODIPY-PC
was added at the stage of lipid ﬁlm formation, except for spectro-
ﬂuorimetry experiments, where 2 mol.% of BODIPY-PC was used. For-
mulations were stored at 4 °C and used for biological experiments
within 10 days.
To control lipid bilayer integrity on incubations in different media,
liposome samples encapsulating calcein at the self-quenching con-
centration were prepared. Lipid ﬁlms were hydrated in PBS with
80 mM calcein and processed as described above; after extrusion,
non-encapsulated calcein was removed by size exclusion chromatogra-
phy on a Sephadex G-50 column equilibrated in PBS. To control the ﬁnal
liposome concentration, calcein andMlph-DOG absorbance peaks were
registered upon liposome disruption with at least 20-fold volume of
ethanol (calcein: λmax 497 nm, ε ~74,000 M−1 cm−1; Mlph-DOG:
λmax 258 nm, ε ~19,700 M−1 cm−1) on an SF-256-UVI two-beam
spectrophotometer (LOMO Fotonika, Russia). Leakage of calcein from
the liposomes and its dilution results in the dequenching of the
ﬂuorophore and increase in the ﬂuorescence signal. The percentage of
calcein released was calculated according to the equation: (Ii/IT – I0/IT) /
(1 – I0/IT) × 100%, where Ii is the ﬂuorescence intensity at given time
point, I0 is the intensity at the beginning of the measurement and IT is
the totally dequenched calcein ﬂuorescence after the addition of Triton
X-100 (1% by vol.). The measurements were performed on a GloMax®-
Multi instrument (Promega) using the blue ﬂuorescence optical kit
(λex 490 nm, λem 510–570 nm).
2.3. Cell culture
Individual donor endothelial cells (HUVEC) were isolates from
human umbilical cords according to the methods of Jaffe [32] and
Scheglovitova [33]. Brieﬂy, fresh umbilical veins were cannulated and
ﬁlled with dispase solution (2 mg/mL) (Gibco) and incubated at 37 °C
for 30min. Then, the veinswere perfused with PBS. Cells were collected
from the perfusate by centrifugation at 1000 rpm for 10 min,resuspended in Medium 199 (Gibco) supplemented with 10% fetal calf
serum (HighClone), 200 μg/mL endothelial growth factor (Sigma),
100 μg/mL heparin (Moscow endocrine plant), 50 μg/mL gentamycin
(KRKA) and seeded into 6-well plates. Cellswere cultured in humidiﬁed
atmosphere of 5% CO2 at 37 °C. The conﬂuent primarymonolayers were
washed and trypsinised (0.05% trypsin + 0.02% EDTA, Gibco). The cells
were resuspended into complete medium, seeded on 24-well plates
(120,000 cells/mL) (Costar), and cultured for four days. For experi-
ments, only the ﬁrst subcultures were used.
Umbilical cordswere obtained after normal parturition fromhealthy
donors following informed written consent.2.4. Confocal microscopy studies
Four days 2-passage HUVECwere seeded on cover slides (~0.5 × 106
cells/mL) pre-coated with 0.2% w/v gelatin (Sigma) and incubated
for 24 h in humidiﬁed atmosphere of 5% CO2 at 37 °C. Then, cells
(with/without activation) were incubated with Hoechst 33342
(Sigma) for 30min to stain nuclei, washedwith DPBS (PBSwith calcium
and magnesium salts, PanEco, Russia) and co-incubated for the stated
time period at 37 °C with the trackers of intracellular organelles and li-
posomes added to a ﬁnal lipid concentration of 50 μM in the serum-free
medium. Liposomes contained none, 2 or 5 mol.% of SiaLeX conjugate.
Before being ﬁxed with 1% paraformaldehyde (PFA) solution, cells
were washed twice with DPBS. For tracking of early endosomes (Trans-
ferrin), Golgi apparatus (WGA) and endoplasmic reticulum (ER-
tracker), co-incubations were performed for 15 min.
Prior to examination on a Nikon TE 2000 Eclipse confocal micro-
scope, slides were mounted with a polymerizing agent Mowiol 4.88 so-
lution (Calbiochem). Image analysis was carried out using ImageJ 1.48
software.2.5. Flow cytometry studies
Cell suspensionswere dilutedwith equal volumes of 1%BSA solution
in PBS and 0.3 μg/mL propidium iodide solution in PBS (the latter being
used to assess cell viability) and analysed on FACScan ﬂow cytometer
(Becton Dickinson), equipped with a 488 nm argon-ion laser. Fluo-
rescence emission signals were detected in FL1 (515–545 nm spectral
window), FL2 (565–610 nm) and FL3 (N650 nm) channels, duplicate
measurements with 10,000 events were recorded for each sample.
Side/forward scatter and propidium iodide ﬂuorescence signals
were used to gate the cell subsets of interest and eliminate debris,
dead cells and cell aggregates. Data were analysed using CELLQuest
software.2.6. E-selectin expression
E-selectin expression by HUVEC in the range of TNF-α concentra-
tions was assessed by FACS analysis and confocal microscopy. Cells
were activated with 0.1–50 ng/mL TNF-α for 4 h at 37 °C. For confocal
microscopy, cells were incubated with anti-human E-selectin antibo-
dies (1:100) for 1 h at 37 °C under gentle shaking, washed with DPBS
and ﬁxed in 1% PFA for 15 min at 37 °C. Cells were then washed with
DPBS 3 times, stained with Alexa Fluor® 555 anti-mouse secondary an-
tibodies for 1 h at 37 °C,washedwith DPBS 3 times and examined under
amicroscope. For FACS analysis, activated cells werewashedwith DPBS,
detached with EDTA solution, resuspended in PBS with 1% BSA and in-
cubated with anti-human E-selectin antibodies (1:100) for 1 h at 4 °C.
Cells were than washed twice in PBS/BSA by centrifugation at 500 g
for 5 min and stained with FITC (488 nm) anti-mouse secondary anti-
bodies for 1 h at 4 °C (detection in FL1 channel).
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To assess the speciﬁcity of SiaLeX liposomes, activated (50 ng/mL
TNF-α, 4 h, 37 °C) HUVEC were pre-treated with excess anti-human
E-selectin antibodies or non-speciﬁc IgG as a control (10 μg/mL, 1 h at
37 °C) followed by treatment with liposomes.
To reduce unspeciﬁc binding and membrane fusion, low-tempera-
ture (4 °C) incubations were applied at certain steps. For confocal mi-
croscopy, after incubation with mAbs, cells were chilled to 4 °C,
washed with cold DPBS and incubated for 1 h on ice with liposomes
(2 mol.% SiaLeX conjugate, 25 μM total lipid in serum-free medium).
Cells were then washed 3 times with cold DPBS, ﬁxed in 1% PFA at 4 °C
overnight, washed with DPBS and examined under a microscope.
For FACS analysis, after incubation with mAbs or control IgG, cells
were rinsed with DPBS and incubated with 10% SiaLeX liposomes
(50 μM of the total lipid in serum-free medium) for 1 h at 37 °C. Cells
were then rinsed 3 times with DPBS, detached with EDTA solution
(10 min, 37 °C) and analysed by FACS.
Relative binding avidity was assessed according to [34] as follows:
cells were chilled to 4 °C, washed with cold DPBS and incubated for
1 h on ice with 2% SiaLeX or control liposomes (50 μM total lipid,
200 μL serum-free medium), then rinsed 3 times with DPBS, treated
with 500 μL of complete medium and incubated for 1 h at 37 °C. Cells
were then rinsed with DPBS, detached with EDTA solution (10 min 37 °C)
and analysed by FACS.
Overall accumulation of liposomes in the range of SiaLeX conjugate
concentrations in the bilayer was characterized by FACS analysis and
confocal microscopy; incubations were set up at 37 °C for 60 min with
50 μM of the total lipid liposomes in serum-free medium.
In the histograms of FACS analysis, when double peak patterns ap-
peared, high-intensity peakswere taken into consideration (see Supple-
mentary data).
2.8. Quantiﬁcation of membrane-bound and internalised liposomes
HUVEC in monolayers in 24-well plates were activated with
10 ng/mL of TNF-α for 4 h at 37 °C, then incubated in 200 μL serum-
free medium for 30 min at 37 °C on a shaker, and then the medium
was replaced with the liposome dispersion (200 μL, 2% SiaLeX or control
liposomes, 3mMtotal lipidwith 2% BODIPY-PC) and incubated for 1 h at
37 °C undermild shaking. Then, cellswerewashed three timeswith PBS
and treated with 0.5 mL of 0.05% trypsin/EDTA solution for 1 or 30 min
at 37 °C. 400 μL of short time–treated cells were collected and
solubilised with 20 μL of 10% Triton X-100 and sonicated for 30 min,
resulting in total cell-associated liposomes. Long time–treated cells
were centrifuged at 1000 g (4 °C, 20 min) to separate precipitated
internalised fractions of liposomes and membrane-bound fractions in
the supernatant [35]. After solubilisationwith Triton X-100, the ﬂuores-
cence of BODIPY-PC in the resulting solution was measured in a quartz
cuvette under constant stirring using Hitachi F4000 spectroﬂuorimeter
with excitation and emission band-pass 5 nm, λex 490 nm and λem
506 nm. The ﬂuorescence intensity was converted to the amount of
cell-associated Mlph-DOG prodrug using calibration curves obtained
with BODIPY-PC-labelled liposomes.Table 1
Effect of the medium and temperature on the size of liposomes after 1 h incubation.a
Conditions Non-targeted
liposomes
2% SiaLeX liposomes
D (nm) PDI D (nm) PDI
PBS, 4 °C 96 ± 1 0.062 91 ± 3 0.055
PBS, 37 °C 98 ± 1 0.085 90.4 ± 0.4 0.052
Serum-free medium, 4 °C 99 ± 2 0.074 92 ± 1 0.062
Serum-free medium, 37 °C 102 ± 1 0.069 91 ± 1 0.094
a According to dynamic light scattering data: D, mean diameter; PDI, polydispersity
index; mean ± SE of the measurements.2.9. Double-labelled liposomes (calcein–rhodamine assay)
To assess liposome uptake by cells and intracellular liposome dis-
ruption,we used a technique described in [36]. Liposomeswere labelled
with 1mol.% Rhod-PE probe in the bilayer and contained 80mM calcein
tetrasodium salt in the water interior. Non-encapsulated calcein was
removed by gel ﬁltration using a Sephadex G-50 column equilibrated
in PBS. Liposome ﬁnal concentration was controlled by Rhod-PE (λmax
556 nm, ε ~82,000 M−1 cm−1), calcein and Mlph-DOG absorbancepeaks. Upon interactions with cells, mean rhodamine ﬂuorescence value
reﬂects the extent of binding and uptake of liposomes, whereas mean
calcein ﬂuorescence reﬂects the intracellular dequenching of the dye.
To calibrate and compensate rhodamine (detection in FL2 channel)
and calcein (detection in the FL1 channel) ﬂuorescent signals in FACS
experiments, single-labelled liposomes were also prepared. When dou-
ble peak patterns appeared, high-intensity peaks were accounted (see
Supplementary data).
Resting or activated HUVECmonolayers in 24-well plates (50 ng/mL
TNF-α, 4 h, 37 °C)were rinsedwith DPBS and incubatedwith liposomes
(5% SiaLeX, 50 μM total lipid, 200 μL) for the stated time period at 37 °C.
Control of bindingwas done by incubating the cells with liposomes at 4 °C,
to prevent uptake and processing of liposomes. Cells then were washed 3
times with cold DPBS, treated with EDTA solution and kept on ice before
FACS analysis.
For confocal microscopy, cells were cooled to 4 °C and incubated
with liposomes (5% SiaLeX, 50 μM in serum-free medium) for 30 min
on ice, washed three times with DPBS and incubated for various time
periods at 37 °C in complete medium. Cells were then ﬁxed with 1%
PFA for 15 min at 37 °C and examined under a microscope.
3. Results
3.1. Liposomes
As assessed by dynamic light scattering, cellmediumor temperature
of incubation had no effect on the size of non-targeted liposomes and
those with 2 mol.% SiaLeX conjugate (Table 1). Exactly the same formu-
lationswere used in our recent study in vivo [23] (see Introduction). The
integrity of liposomes was also retained during 1-h incubations accord-
ing to the calcein leakage assay (Fig. 2). Slight initial release of calcein
(3–4%) may occur due to the dissolution of trace amounts of calcein
adsorbed on the surface of liposomes due to 60-fold dilution of the sam-
ples before measurements. The averaged release in PBS was somewhat
higher than that in the cell medium, probably due to differences in the
compositions of the dispersing solutions (in addition to inorganic
salts, Medium 199 contains nucleotides, nucleosides and vitamins).
The increase in SiaLeX conjugate content in lipid bilayer from 2 to
10 mol.% did not inﬂuence the size of the liposomes, as assessed by dy-
namic light scattering (Supplementary data, Table S1).
3.2. E-selectin expression
Being primary cells from an individual donor, HUVEC may exhibit
unique activity upon inﬂammatory cytokine activation. We have ob-
served several instances in which there was a slight original expression
of E-selectin (data not shown), but these cell samples were not used in
further experiments. We explored the expression of E-selectin in
response to TNF-α activation in a range of concentrations (from 0.1 to
50 ng/mL) by ﬂow cytometry and confocal microscopy. Without activa-
tion, no detectable amount of E-selectin appeared, while activation with
increasing TNF-α concentrations led to an exponential increase in its
expression (Fig. 3A). Importantly, according to ﬂow cytometry data,
three populations of cells with different levels of E-selectin
Fig. 2. Liposome stability. Calcein leakage from liposomes during 1 h incubation in PBS
(black) or serum-free medium (red), mean ± SD, n= 3.
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majority of studied cell batches. Fig. 3B displays a typical FACS analysis
histogram. High-intensity population proportion increased with growing
TNF-α concentrations, but even at 50 ng/mL TNF-α, a population with
low level of E-selectin expression was present. For our study, we
employed this concentration of TNF-α, since it provided maximal up-
regulation without visible cytotoxic effects. The confocal microscopy
data (Fig. 3C) evidence massive expression of E-selectin molecules after
activation with the maximal studied cytokine concentration.Fig. 3. E-selectin expression on the HUVEC endothelial cells. Cells were activated with differen
selectinmAb for 1 h at 4 °C, stainedwith FITC-labelled secondaryAb for 1 h at 4 °C and analysed
mean ± SD; *, data for one experiment, mean ± SE (A). Representative ﬂow cytometry histog
tested TNF-α concentrations (B). HUVEC monolayers with or without activation were incubat
stained with Alexa-555-labelled secondary Ab (red) for 1 h at 37 °C and examined under a mi3.3. Accumulation of liposomes by HUVEC
Initially, relative binding avidity of HUVEC for targeted and non-
targeted liposomes in the range of the ligand concentrations was
explored according to [34]. Activated or non-activated cells were incu-
bated with the formulations under endocytosis-blocking conditions
(at 4 °C); then, the cells were allowed to consume surface-bound lipo-
somes (at 37 °C) and were analysed by FACS. Non-activated HUVEC
bound targeted liposomes with low avidity approximately equal to
that one exhibited by the activated cells towards SiaLeX-free liposomes
(Fig. 4A, blank bars). Only in the case of both activated cells and targeted
liposomes did double peak histograms appear, with high-intensity ﬂuo-
rescence peaks evidencing speciﬁc interactions between SiaLeX ligand
of liposomes and E-selectins on the cell surface (shown by the example
of 10% SiaLeX liposomes in Fig. 4B; for other histograms, see Supplemen-
tary data). The lowest concentration of SiaLeX conjugate in liposomes (2
mol.%) generated a four-fold increase in ﬂuorescence signals over non-
activated cells, while the growth of ligand concentration up to 10% re-
sulted in a 14-fold increase (Fig. 4A, ﬁlled bars).
Next, we explored the impact of SiaLeX ligand on the overall accu-
mulation of liposomes by functioningHUVEC (at 37 °C). At physiological
temperature, non-activated cells consumed about 10 times more lipo-
somes than at 4 °C (Figs. 5A and 4A). The increase in SiaLeX content in
liposomes from 2 to 10 mol.% led to about 6-fold increase in the lipo-
some accumulation by activated cells, while non-activated HUVEC
retained initial levels of liposome binding and uptake (Fig. 5A). Accord-
ing to confocalmicroscopy, all formulations exhibited diffuse staining in
the case of non-activated cells (as shown by the example of 5% SiaLeX li-
posomes; Fig. 5B). In the case of activated cells, targeted liposomes ap-
peared in the cytoplasm as bright spots, while SiaLeX-free onest TNF-α concentrations for 4 h, then detached with EDTA solution, incubated with anti-E-
byﬂowcytometry; average data on the total population in three independent experiments,
rams; populations with no, middle and high response to activation were observed for all
ed with E-selectin mAb for 1 h at 37 °C, stained with Hoechst for nuclei (blue), ﬁxed and
croscope; the bar is 5 μm (C).
Fig. 4. Liposome (L) avidity. Resting or activated with TNF-α (50 ng/mL), HUVEC were incubated for 1 h on ice with BODIPY-PC-labelled liposomes (50 μM total lipid) bearing 0, 2, 5 or
10mol.% SiaLeX conjugate (10% SiaLeX-L), rinsed and incubated in completemedium for 1 h at 37 °C; then, cellswere detachedwith EDTA solution and analysed byﬂowcytometry; data of
a representative experiment, mean± SE, are reported (A). An example of typical FACS histograms for binding of liposomeswith HUVEC: highly intensive population represents cells that
bound liposomes mostly via E-selectin–SiaLeX interactions (B).
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results of FACS analysis and evidence the internalisation of SiaLeX lipo-
somes by the activated HUVEC.
The speciﬁcity of SiaLeX liposome interactionswith activated HUVEC
was established by competitive inhibition of binding with anti-E-
selectin mAb. First, the activated cells were treated with the excess of
anti-E-selectin mAb (or non-speciﬁc IgG). Further incubation of cells
with 10% SiaLeX liposomes at 37 °C allowed registering reliable differ-
ences in ﬂow cytometry experiments. Control IgG practically did notFig. 5. Overall accumulation of liposomes by HUVEC in function of activation and the content o
cubated for 1 h at 37 °Cwith BODIPY-PC-labelled liposomes (greenﬂuorescence, 50 μMtotal lipi
data of a representative experiment are presented (mean± SE), # p N 0.01, * p b 0.01; or (B) th
analysed by confocal microscopy. The bar is 10 μm.change the overall accumulation of liposomes by cells, while speciﬁc
mAb inhibited the consumption of liposomes by 70%, diminishing lipo-
some accumulation practically to the level of non-activated HUVEC
(Fig. 6A). To observe the inhibition of speciﬁc liposome bindingwith ac-
tivatedHUVEC by confocalmicroscopy (Fig. 6B), we used 2% SiaLeX lipo-
somes and low-temperature incubations at 4 °C to reduce non-speciﬁc
binding andmembrane fusion. Indeed, in the presence of excess speciﬁc
mAb, bright punctuated patterns of bound SiaLeX liposomes contouring
plasmamembranes (Fig. 6B, central image) changed to theweak diffusef SiaLeX conjugate in liposomes. Resting or activated with TNF-α (50 ng/mL) cells were in-
d) and rinsed. Then, (A) the cells were detachedwith EDTA solution and analysed by FACS;
e cells were stained with Hoechst for nuclei (blue), ﬁxedwith 1% PFA overnight at 4 °C and
Fig. 6.The speciﬁcity of binding of SiaLeX liposomeswithHUVEC. Activated (50 ng/mL TNF-α) or resting cellswere pre-treatedwith the excess of E-selectinmAb (10 μg/mL, 1 h at 37 °C) or
non-speciﬁc IgG as a control, with subsequent treatment with BODIPY-PC-labelled liposomes (green ﬂuorescence). (A) Cells were incubatedwith 10% SiaLeX liposomes (50 μM total lipid,
1 h at 37 °C), rinsed, detachedwith EDTA solution and analysed by ﬂow cytometry. Data of a representative experiment (mean± SE) are reported. (B) Activated cells were incubatedwith
non-targeted or 2% SiaLeX liposomes (25 μM total lipid, 1 h at 4 °C) with or without mAb pre-treatment, stained with Hoechst for nuclei (blue), ﬁxedwith 1% PFA for 15min at 37 °C and
analysed by confocal microscopy. The bar is 5 μm.
Fig. 7. Spectroﬂuorimetry of cell fractions. Liposomes (3 mM total lipid, 2% BODIPY-PC, 2%
SiaLeX conjugate) were incubatedwith HUVEC for 1 h at 37 °C. Then, the cells were rinsed
and treatedwith trypsin/EDTA solution for 1 or 30min at 37 °C. Shortly treated cells were
solubilised with 0.5% Triton X-100 solution with subsequent sonication for 30 min at 37 °C;
these comprised the total liposomes accumulated by the cells (Total). Long-term treated
cellswere centrifugedwith subsequent TritonX-100 andultrasound solubilisation of thepre-
cipitate (IL, internalised liposomes) and supernatant (BL, bound or membrane-associated li-
posomes). BODIPY-PC ﬂuorescence signal was measured and converted to Mlph-DOG
content using the calibration curve. Mean ± SD for two independent experiments are
presented.
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(Fig. 6B, left image). Non-activated HUVEC showed low amounts of
bound liposomes and diffuse patterns of staining, similar to the case of
SiaLeX-free liposomes and activated cells, independently of thepresence
of SiaLeX ligand (data not shown).
3.4. Quantiﬁcation of membrane-bound and internalised liposomes
Incorporation of as little as 2 mol.% of SiaLeX conjugate in the bilayer
of liposomes in the in vivo experiment [23] resulted in a pronounced
antivascular effect and exhibited a different distribution in the tumour
tissue as compared to the SiaLeX-free counterpart. It was interesting to
explore whether this difference was caused by an increase in the con-
sumption of liposomes or in their binding.
To quantify membrane-bound and internalised liposomes after in-
cubation with cells, we used spectroﬂuorimetry. According to [35], the
membrane-bound fraction of liposomes can be separated by prolonged
treatment of cells with trypsin (30min at 37 °C instead of the ordinarily
1–5 min used for the detachment of cells from cultural plates), which
results in glycocalyx shedding and liposome dissociation from the cell
surface. After centrifugation, the supernatant contains membrane-
bound liposomal fraction, and the pellet contains cells with internalised
liposomes.
According to ﬂuorescence spectroscopy data (Fig. 7), both
processes—binding and internalisation of liposomes by activated
HUVEC—were 40–50% more efﬁcient in the case of SiaLeX liposomes if
compared to thenon-targeted formulation. The effect of targeting ligand
on liposome total accumulation by activated cells as compared to non-
activated ones (~8% increase, Fig. 7) is not as pronounced as the effect
exhibited in the ﬂow cytometry experiments (~33% increase for 2%
SiaLeX liposomes; Fig. 5A). There are at least two reasons for this. First,
to ensure reliable sensitivity of measurements, we increased the con-
centration of liposomes in the incubation media from 50 μM (as used
in the ﬂow cytometry experiments) to 3 mM of total lipids. This in-
creased non-speciﬁc interactions of liposomes with cells to the level ex-
ceeding/beating/surpassing the impact of speciﬁc interactions between
SiaLeX ligand and E-selectin. Second, in contrast to ﬂuorescence spec-
troscopy, where lysates from the whole pool of cells were analysed, in
FACS analysis, we evaluated speciﬁc subsets of cells. In any case,
spectroﬂuorimetry data evidence that 2% SiaLeX liposomes bind and
enter activated HUVEC more efﬁciently than SiaLeX-free formulations.
Based on the measured content of Mlph-DOG in cell fractions
(4 × 10−11 mol; Fig. 7), the theoretical number of Mlph-DOGmolecules
per 100 nm liposome (~8000) and the average number of assayed cellsof about 2 × 105, one may recalculate that in medium with an excess of
liposomes, activated HUVEC accumulate approximately 15,000 lipo-
somes per cell within an hour.
3.5. Intracellular delivery
To monitor the early stages of intracellular trafﬁc of targeted lipo-
somes in the activated HUVEC, we evaluated co-localisation of lipo-
somes with the intracellular organelle trackers. Here, we used
liposomes with intermediate amounts of SiaLeX conjugate (5 mol.%) to
obtain reliable results and avoid ﬂaring of images. Within 15 min of in-
cubation, liposomes were observed inside the cells (Fig. 8). Staining
with the wheat germ agglutinin (WGA) clearly deﬁned the cellular out-
line of the glycocalyx and the bright spots of the Golgi apparatus
(Fig. 8B). Diffuse green stainingmostly co-localised with the area of en-
doplasmic reticulum (Fig. 8A),while bright green spots corresponded to
Golgi and, partly, to the early endosomes (Fig. 8C). Interestingly, co-
Fig. 8. Intracellular delivery of targeted liposomes labelledwith BODIPY-PC in themembrane (green). Co-localisation with endoplasmic reticulum (ER), early endosomes (Trf), glycocalyx
and Golgi apparatus (WGA, wheat germ agglutinin) trackers (red). Activated with 50 ng/mL TNF-α, HUVEC were prestained with Hoechst for nuclei (blue), co-incubated with 5% SiaLeX
liposomes (50 μMtotal lipid) and the trackers for 15min at 37 °C and thenﬁxedwith 1%PFA for 15min at 37 °C. Cellswere visualised using confocalmicroscopy and are presented as single
z-scans; the bar is 10 μm.
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endocytosis pathway (transferrinmolecule enters the cell through a re-
ceptor localised in classical coated pits), was only partial (Fig. 8C). Thus,
the presence of SiaLeX conjugate in liposomes brought an additional,
clathrin-independent internalisation pathway. Non-targeted liposomes
did not show such punctuated patterns of staining (Fig. 5B). Diffuse
character of staining indicates rather the passive fusion of liposomes
with the cell membrane than the active transport of SiaLeX liposomes
mediated through E-selectin molecules.
Thus, the preliminary picture of the early stages of internalisation of
targeted liposomes by activated endothelial cells may be as follows:
after bindingwith E-selectinmolecules, liposomes undergo endocytosis
followed by sorting and transport to Golgi and ﬁnally approach the en-
doplasmic reticulum. Yet, what is the state of the liposomes during
these events?Do they retain the integrity beingdispersed inwater com-
partments of intracellular organelles? Or does the liposomal bilayer fusewith the cell membranes and thereby unload the lipophilic prodrug fa-
cilitating its presentation to intracellular esterases?
3.6. Kinetics of liposome binding, uptake and intracellular disruption
To follow the binding of targeted liposomes by HUVEC, their uptake
and intracellular disruption, we used FACS analysis involving dual ﬂuo-
rescence labelling, as suggested in [36].Weprepared double-labelled 5%
SiaLeX liposomes bearing lissamine rhodamine B ﬂuorophore in the bi-
layer (Rhod-PE probe) and encapsulating calcein in thewater interior at
a self-quenching concentration. Accordingly, the total accumulation of
liposomes in cells was monitored by measuring rhodamine ﬂuores-
cence and liposome disruption by ﬂuorescence of calcein. Non-
activated HUVEC showed very low accumulations of both targeted
(Fig. 9A) and non-targeted (data not shown) formulations until up to
90-min of monitoring; calcein release was also negligible (Fig. 9B). On
Fig. 9. Binding (Rhod-PE signal) and dynamics of intracellular disruption (calcein signal) of 5% SiaLeX liposomes (50 μM total lipid) upon incubation with resting (A and B) and TNF-α-
activated (C and D) HUVEC at 37 °C (solid line) or 4 °C (dashed line). The membrane of liposomes is labelled with Rhod-PE and calcein is encapsulated at self-quenching concentration.
At 37 °C, activatedHUVEC bound SiaLeX liposomeswith saturation after ~40min and the bindingwas accompanied by rapid (withinminutes) internalisation process resulting in liposome
membrane disruption. Under low temperature, binding was drastically reduced, while liposome membranes remained intact. Non-activated cells consumed a negligible amount of lipo-
somes at both temperatures. Flow cytometry data of a representative experiment (mean ± SE) are presented.
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tion after ~40 min (Fig. 9C), the uptake being accompanied by rapid
(within minutes) liposome membrane disruption (Fig. 9D). The data
of confocal microscopy agrees with the results of ﬂow cytometry
(Fig. 10): indeed, images show intact liposomes bound to plasmalemma
as small red spots after low-temperature incubation (0 min) with acti-
vated HUVEC; after 40/90min incubation at physiological temperature,
liposomes were detected in the cytosol as large green and yellow (due
to the overlap of red and green ﬂuorescence) areas.4. Discussion
The study compares SiaLeX-equipped liposomes loaded with lipo-
philic prodrug of an anticancer agentmelphalan and SiaLeX-free formu-
lation regarding the interactions with activated and non-activated
endothelial cells. We were interested in the exploration of both the
targeting potential of our speciﬁcally designed formulation and the
mechanism of its uptake by the cells, which determines subsequent in-
tracellular trafﬁc of liposomes and release of the cargo. As the prodrug
may be considered a lipidic diglyceride molecule, well ﬁtted and stably
included in the lipid bilayer, we suppose that labelling of liposomeswith
phospholipid ﬂuorescent probes (BODIPY-PC, Rhod-PE) allows moni-
toring the fate of lipophilic prodrug Mlph-DOG at least until liposomes
retain their integrity. The study was performed using a number of ﬂuo-
rescent techniques and methodologies.Fig. 10. Confocal microscopy images of the uptake of targeted liposomes by activated HUVEC
calcein (green) at self-quenching concentration; cell nuclei are stained with Hoechst (blue). Pr
50 μM) for 30 min on ice, washed and incubated for various time periods at 37 °C in a completEndothelial cells transiently express E-selectin and present it on the
surface in response to stimulation by inﬂammatorymolecules [37], such
as tumour necrosis factor (TNF-α) and interleukin-1. After cell exposure
to cytokines, E-selectin expression temporally changes, reaching its
maximum 4 h after stimulation and then rapidly decreasing—E-selectin
is no longer detectable on cell surface after 24 h [37] due to constitutive
internalisation by endocytosis [38]. For this reason, studies on targeting
E-selectin in vitro are performed after 3–4 h incubations of HUVECwith
the cytokines [39,40].
For our experiments, we selected activating concentration of TNF-α
basing on the maximal level of E-selectin expression obtained within
the studied range of concentrations (0.1–50 ng/mL). It is unlikely that
further increase of cytokine concentration could result in the substantial
increment of E-selectin expression, exponential increase of which
ended shortly after reaching TNF-α concentration of 1 ng/mL
(Fig. 3A). Stimulation by TNF-α generally led to high levels of E-
selectin expression in a major population of cells; however, even at
the maximal level of expression, a fraction not responding to activation
persisted among the cells (Fig. 3B).
The potential of targeting of our liposomal formulation was evaluat-
ed in the function of the concentration of SiaLeX conjugate. Here, we
used the advantage of FACS analysis and speciﬁcally took into con-
sideration only the ﬂuorescence signal of the highly intensive cell pop-
ulations. The contribution of SiaLeX ligand (10 mol.%) to interactions
of liposomes with activated HUVEC assessed by the relative binding
avidity assay (Fig. 4A), in which non-speciﬁc interactions with the. The liposome membrane is labelled with Rhod-PE (red) and the inner volume contains
ior to the experiment, cells were cooled to 4 °C and incubated with liposomes (5% SiaLeX,
e medium. The bar is 5 μm.
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resulted in a 14-fold increase in liposome binding over non-targeted for-
mulations. The formulation with 2 mol.% SiaLeX ligand provided only a
four-fold increase; nevertheless, even for this formulation, we have
shown an undoubtable targeting to tumour endothelium in vivo [23].
The liposomes are negatively charged due to the relatively high content
of phosphatidylinositol (10 mol.%) in the bilayer: their zeta potential is
around−30 mV [23]. Logically, this would hamper the interactions be-
tween liposomes and cells, most of which express negatively charged
(mainly sulfated) proteoglycans on the surface [41]. The gradual addition
of SiaLeX conjugate up to 10mol.% should only further increase the nega-
tive charge of liposomes due to the non-protonated carboxyls of the sialyc
acid residues. However, these formulations exhibited the growth of avid-
ity to HUVEC, thus evidencing the contribution of speciﬁc polyvalent
interactions between SiaLeX ligands of liposomes and multiple copies of
E-selectin at the cell surface. The persisting low level of binding of
liposomes with non-activated cells, independently of the presence of
SiaLeX conjugate, also proves the contribution of speciﬁc interactions
with E-selectin (Fig. 4). At physiologically relevant temperatures, the ef-
fect of SiaLeX ligand on liposome accumulation by HUVEC showed the
same tendency: an approximately 6-fold increase of accumulated quanti-
ties of 10% SiaLeX liposomes in activated cells against the retained level in
the case of non-activated HUVEC (Fig. 5A). Here, the effect is less pro-
nounced due to the involvement of a diversity of non-speciﬁc interactions
in the course of endocytosis. Finally, both the inhibition of targeted lipo-
some accumulation in activated HUVEC with anti-E-selectin mAb and
the absence of such inhibition with non-speciﬁc IgG conﬁrm the impact
of SiaLeX ligand on speciﬁc interactions with E-selectin (Fig. 6A).
The speciﬁcity of binding of SiaLeX liposomes with activated chilled
HUVEC is clearly visualised by confocal microscopy (Fig. 6B). Further,
the microscopy patterns obtained for functioning cells (at 37 °C) not
only corroborate thedependence of liposome accumulation upon SiaLeX
concentration but also demonstrate quite a different type of intracellu-
lar distribution of targeted formulations, implying their inclusion in the
intracellular organelles of activated HUVEC (Fig. 5B).
To quantitatively discriminate between membrane-bound and
internalised (consumed) liposomes, ﬂuorescence spectroscopy was
used. The technique permits the assessment of values averaged over
the whole pool of cells under study, without gating cell subsets of inter-
est afforded by FACS analysis. As opposed to the commonly usedmalig-
nant cell lines, HUVEC do not proliferate but simply survive, so their
consuming activity is moderate. To meet the lower sensitivity of the
spectroﬂuorimetry technique, the concentration of liposomes in the in-
cubation media was taken 60 times higher than that used in the exper-
iments with ﬂow cytometry and confocal microscopy. This could
actually elevate the contribution of non-speciﬁc interactions to the
level that downplays the effect of high-afﬁnity polyvalent interactions
between SiaLeX ligand and E-selectin. Upon a balance, good agreement
between the quantitative results of the inﬂuence of 2 mol.% SiaLeX con-
jugate in liposomes on their overall accumulation by the activated
HUVEC obtained with two different ﬂuorescence methods (about 35%,
Figs. 5A and 7 in a set of bars “total”) is a lucky chance. Another matter
is that spectroﬂuorimetry yet evidences more efﬁcient binding and
internalisation of targeted liposomes by activated cells as compared to
both SiaLeX-free formulations and non-activated cells. Also, the tech-
nique revealed no essential differences between the bound-to-
internalised liposome ratios: for all four studied combinations of formu-
lations and cells (targeted/non-targeted liposomes and activated/non-
activated cells) the ratio was close to 2 (Fig. 7), that is, only 50% of
bound liposomes entered the cells. This is not that far from the results
obtained in a study by Kessner et al. [39], who used the so-called
dithionite quenching technique with N-(7-nitro-2-1,3-benzoxadiazol-
4-yl)-labelled liposomes initially bound on the cell surface at 4 °C and
then allowed it to be consumed at 37 °C. Regardless of the presence or
the speciﬁcity of the coupled antibodies, 70-nm liposomes equipped
with anti-E selectin mAb or IgG in a varying manner—at the distal endof PEG-2000 derivatised phosphatidylethanolamine or near the polar
head group of the phospholipid—demonstrated internalisation of not
more than 20–25% of bound liposomes by activated HUVEC (about
3100 liposomes per cell).
Nevertheless, different patterns of intracellular distribution of
BODIPY-labelled PC after 1-h incubations of targeted/non-targeted lipo-
someswith activated/non-activated cells (Fig. 5B; SiaLeX-free liposomes
in the resting cells exhibited weak diffuse staining, data not shown)
indicate the implementation of active transport in the uptake of SiaLeX
liposomes by activated HUVEC. Monitoring the early stages of intracel-
lular trafﬁc (Fig. 8), we found that endocytosis of SiaLeX liposomes oc-
curred only partially via clathrin-dependent pathway, which does not
contradict the available literature data on E-selectin localisation in plas-
malemma. Indeed, it has been demonstrated that E-selectin clusterises
in both clathrin-coated pits and lipid rafts of endothelial cells (although
its internalisation has been shown to proceed only through clathrin-
coated pits) [43]. Moreover, in an early study by von Asmuth et al.
[38], who immunostained E-selectins in the electron microscopy cryo-
sections of TNF-α-activated HUVEC with colloidal gold, the observed
number of clathrin-coated pits and clathrin-coated vesicles was too
small to allow for a conclusion about the involvement of these struc-
tures in the process of E-selectin internalisation. In general, our targeted
liposomes seem to follow the endocytosis track through endosomes and
sorting to Golgi followed by entering endoplasmic reticulum, as it is
outlined in [42] for both clathrin-dependent endocytosis and ﬂuid
phase uptake.
It was demonstrated bypyranine spectroscopic [39] andmicroscopic
[40] assays that E-selectin-targeted immunoliposomes of various com-
positions underwent, at least in part, endosome/lysosome pathway
appearing in acidic perinuclear vesicles 2–4 h after binding to the cell
surface [40]. At the same time,microscopic investigation showed that li-
posomes also fused with the cell membrane and the entrapped calcein
was released into the cytoplasm in 90-min incubations [39]. Further,
the authors [18] found that SiaLeX-conjugated liposomes composed
mainly of egg phosphatidylcholine and loaded with antisense oligonu-
cleotides down-regulated protein expression in activated HUVEC with-
out affecting mRNA expression, which evidences that hybridization
with the target mRNA proceeds in the cytoplasm but not in the nucleus.
Using dual ﬂuorescence labelling and FACS analysis, we found that our
SiaLeX formulations—liposomes loaded with melphalan lipophilic
prodrug in the bilayer—undergo rapid internalisation by activated
HUVEC accompanied by the disruption of liposomes, which starts prac-
tically immediately after their uptake and continues for at least 90 min
(Fig. 9D). This process is visualised by the patterns of confocalmicrosco-
py (Fig. 10). We may hypothesize that liposomal membranes fuse with
endosomal membranes at the very early stages and undergo trafﬁcking
preferably to the endoplasmic reticulum, since the most extensive co-
localisation was observed exactly with this organelle, which accounts
for the intracellular transport of membrane-bound molecules (Fig. 8).
If so, SiaLeX liposomes under study have a fair chance to escape lyso-
somal degradation prior to presentation of the lipophilic prodrug to
esterases for the release of the cytotoxic drug, so that it can reach the
nucleus and induce speciﬁc DNA inter-strand cross-linkages in the en-
dothelial cells. This assumption agrees with the apoptotic cell death–
mediated antivascular effect exhibited by these formulations in vivo in
amousemodel of lung carcinoma, which resulted in tumour growth in-
hibition [23]. Another possible route for SiaLeX liposomes is to enter an
endothelial cell through caveolae-mediated pathway and fuse with the
so-called membrane-bound vesicles. The lipophilic prodrug then could
undergo transport from one side of the cell to the other within these
vesicles avoiding any endosomal compartment (such transcytosis is
characteristic of endothelial cells) [44]. Furthermore, the lipophilic
prodrug or the released melphalan itself can exit the cell from the
abluminal surface and further actuate the cytotoxic effect towards tu-
mour cells or their microenvironment. However, both hypotheses
should be the subject of further research.
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doses of liposomes during at least 1.5 h (Fig. 9A, B). The apparent mis-
match of this result with the data on overall accumulation of BODIPY-
labelled liposomes by resting cells (Fig. 5A) should be related to the dif-
ferent photophysical characteristics of rhodamine and BODIPY
ﬂuorophores used. In frames of a single experimental approach with
the same ﬂuorescent label, non-activated and activated HUVEC demon-
strated drastic contrast in the rate of binding and internalisation of
SiaLeX formulations (Fig. 9A, C). This ﬁnding is the primary one in
viewof therapeutic potential of the liposomes since it promises good se-
lectivity towards inﬂamed endothelium inherent to tumour microenvi-
ronment after intravenous administration of the targeted formulations.
In conclusion, in this study, we demonstrate that binding and
internalisation of SiaLeX liposomes loaded with melphalan lipophilic
prodrug in the bilayer by cytokine-activated endothelial cells are essen-
tiallymore efﬁcient if compared to non-activated cells. This selective ef-
fect is realised through speciﬁc cell–liposome interactions upon cell
stimulation and E-selectin exposure on the cell surface. The endocytosis
of SiaLeX liposomes occurs mostly via clathrin-independent pathways,
which increases the possibility of evading lysosomal degradation.
After internalisation, the liposomemembrane undergoes rapid destabi-
lization presumably allowing a facilitated esterase hydrolysis of the
cargo with the release of the cytotoxic agent. The inﬂuence of dynamic
conditions of capillary blood ﬂow on the binding capacity of SiaLeX for-
mulation and endothelial cells is the subject of ongoing studies.
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